ORCA
Online Research @ Cardiff

Clear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Number of items: 102.

Gökbuget, Nicola, Boissel, Nicolas, Chiaretti, Sabina, Dombret, Herve, Doubek, Michael, Fielding, Adele K., Foà, Robin, Giebel, Sebastian, Hoelzer, Dieter, Hunault, Mathilde, Marks, David I, Martinelli, Giovanni, Ottmann, Oliver G.

, Rijneveld, Anita W., Rousselot, Philippe, Ribera, Josep-Maria and Bassan, Renato 2024. Diagnosis, prognostic factors and assessment of ALL in adults: 2023 ELN recommendations from a European Expert Panel. Blood 143 (19) , pp. 1891-1902. 10.1182/blood.2023020794

Gökbuget, Nicola, Boissel, Nicolas, Chiaretti, Sabina, Dombret, Hervé, Doubek, Michael, Fielding, Adele, Foà, Robin, Giebel, Sebastian, Hoelzer, Dieter, Hunault, Mathilde, Marks, David I., Martinelli, Giovanni, Ottmann, Oliver

, Rijneveld, Anita, Rousselot, Philippe, Ribera, Josep and Bassan, Renato 2024. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood 143 (19) , pp. 1903-1930. 10.1182/blood.2023023568
Item availability restricted.

Dolton, Garry, Rius, Cristina, Wall, Aaron, Szomolay, Barbara

, Bianchi, Valentina, Galloway, Sarah A.E., Hasan, MD Samiul, Morin, Theo, Caillaud, Marine, Thomas, Hannah L., Theaker, Sarah, Tan, Li Rong, Fuller, Anna, Topley, Katie, Legut, Mateusz, Attaf, Merriem, Hopkins, Jade R., Behiry, Enas, Zabkiewicz, Joanna

, Alvares, Caroline

, Lloyd, Angharad, Rogers, Amber, Henley, Peter, Fegan, Chris

, Ottmann, Oliver

, Man, Stephen

, Crowther, Michael D., Donia, Marco, Svane, Inge Marie, Cole, David

, Brown, Paul E., Rizkallah, Pierre

and Sewell, Andrew K.

2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186 (16) , pp. 3333-3349. 10.1016/j.cell.2023.06.020

Mauro, Michael J., Hughes, Timothy P., Kim, Dong-Wook, Rea, Delphine, Cortes, Jorge E., Hochhaus, Andreas, Sasaki, Koji, Breccia, Massimo, Talpaz, Moshe, Ottmann, Oliver

, Minami, Hironobu, Goh, Yeow Tee, DeAngelo, Daniel J., Heinrich, Michael C., Gómez-García de Soria, Valle, le Coutre, Philipp, Mahon, Francois-Xavier, Janssen, Jeroen J. W. M., Deininger, Michael, Shanmuganathan, Naranie, Geyer, Mark B., Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, Hoch, Matthias and Lang, Fabian 2023. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia 37 , pp. 1048-1059. 10.1038/s41375-023-01860-w

Sternsdorf, Thomas, Puccetti, Elena, Jensen, Kirsten, Hoelzer, Dieter, Will, Hans, Ottmann, Oliver Gerhard

and Ruthardt, Martin

2023. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Molecular and Cellular Biology 19 (7) , pp. 5170-5178. 10.1128/mcb.19.7.5170

Chiriches, Claudia

, Khan, Dilawar, Wieske, Maria, Guillen, Nathalie, Rokicki, Michal, Guy, Carol, Wilson, Marieangela, Heesom, Kate J., Ottmann, Oliver Gerhard

and Ruthardt, Martin

2022. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia. Annals of Hematology 101 , pp. 2179-2193. 10.1007/s00277-022-04905-9

Chiriches, Claudia

, Nicolaisen, Nathalie, Wieske, Maria, Elhaddad, Heba, Mehmetbeyoglu, Ecmel, Alvares, Caroline

, Becher, Dörte, Hole, Paul, Ottmann, Oliver Gerhard

and Ruthardt, Martin

2022. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation. PLoS Genetics 18 (10) , e1010463. 10.1371/journal.pgen.1010463

Tazi, Yanis, Arango-Ossa, Juan E., Zhou, Yangyu, Bernard, Elsa, Thomas, Ian, Gilkes, Amanda, Freeman, Sylvie, Pradat, Yoann, Johnson, Sean J., Hills, Robert, Dillon, Richard, Levine, Max F., Leongamornlert, Daniel, Butler, Adam, Ganser, Arnold, Bullinger, Lars, Döhner, Konstanze, Ottmann, Oliver

, Adams, Richard

, Döhner, Hartmut, Campbell, Peter J., Burnett, Alan K., Dennis, Michael, Russell, Nigel H., Devlin, Sean M., Huntly, Brian J. P. and Papaemmanuil, Elli 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13 (1) , 4622. 10.1038/s41467-022-32103-8

Konopleva, Marina Y., Röllig, Christoph, Cavenagh, Jamie, Deeren, Dries, Girshova, Larisa, Krauter, Jürgen, Martinelli, Giovanni, Montesinos, Pau, Schäfer, Jonas A., Ottmann, Oliver G.

, Petrini, Mario, Pigneux, Arnaud, Rambaldi, Alessandro, Recher, Christian, Rodriguez-Veiga, Rebeca, Taussig, David, Vey, Norbert, Yoon, Sung-Soo, Ott, Marion Gabriele, Muehlbauer, Susanne, Beckermann, Benjamin M., Catalani, Olivier, Genevray, Magali, Mundt, Kirsten Elisabeth, Jamois, Candice, Fenaux, Pierre and Wei, Andrew H. 2022. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Advances 6 (14) , pp. 4147-4156. 10.1182/bloodadvances.2021006303

Sessa, C., Cortes, J., Conte, P., Cardoso, F., Choueiri, T., Dummer, R., Lorusso, P., Ottmann, O.

, Ryll, B., Mok, T., Tempero, M., Comis, S., Oliva, C., Peters, S. and Tabernero, J. 2022. The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective. ESMO Open 7 (1) , 100339. 10.1016/j.esmoop.2021.100339

Oppliger Leibundgut, Elisabeth, Haubitz, Monika, Burington, Bart, Ottmann, Oliver G.

, Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A., Röth, Alexander, Snyder, David S. and Baerlocher, Gabriela M. 2021. Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. Haematologica 106 (9) , pp. 2397-2404. 10.3324/haematol.2020.252817

Mian, Afsar Ali, Haberbosch, Isabella, Khamaisie, Hazem, Agbarya, Abed, Pietsch, Larissa, Eshel, Elizabeh, Najib, Dally, Chiriches, Claudia

, Ottmann, Oliver

, Hantschel, Oliver, Biondi, Ricardo M., Ruthardt, Martin

and Mahajna, Jamal 2021. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants BCR/ABL1T315I and BCR/ABL1T315I-E255K. Annals of Hematology 100 , pp. 2023-2029. 10.1007/s00277-020-04357-z

Döhner, Hartmut, Symeonidis, Argiris, Deeren, Dries, Demeter, Judit, Sanz, Miguel A., Anagnostopoulos, Achilles, Esteve, Jordi, Fiedler, Walter, Porkka, Kimmo, Kim, Hee-Je, Lee, Je-Hwan, Usuki, Kensuke, D?Ardia, Stefano, Jung, Chul Won, Salamero, Olga, Horst, Heinz-August, Recher, Christian, Rousselot, Philippe, Sandhu, Irwindeep, Theunissen, Koen, Thol, Felicitas, Döhner, Konstanze, Teleanu, Veronica, DeAngelo, Daniel J., Naoe, Tomoki, Sekeres, Mikkael A., Belsack, Valerie, Ge, Miaomiao, Taube, Tillmann and Ottmann, Oliver

2021. Adjunctive volasertib in patients with acute myeloid leukemia not eligible for standard induction therapy: a randomized, phase 3 trial. HemaSphere 5 (8) , e617. 10.1097/FHS9.0000000000000617

Martinelli, Giovanni, Boissel, Nicolas, Chevallier, Patrice, Ottmann, Oliver

, Gökbuget, Nicola, Rambaldi, Alessandro, Ritchie, Ellen K., Papayannidis, Cristina, Tuglus, Catherine A., Morris, Joan D. and Stein, Anthony 2021. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study. European Journal of Cancer 146 , pp. 107-114. 10.1016/j.ejca.2020.12.022

Lang, Fabian, Wunderle, Lydia, Badura, Susanne, Schleyer, Eberhard, Brüggemann, Monika, Serve, Hubert, Schnittger, Susanne, Gökbuget, Nicola, Pfeifer, Heike, Wagner, Sebastian, Ashelford, Kevin

, Bug, Gesine and Ottmann, Oliver G.

2020. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia. BMC Pharmacology and Toxicology 21 (1) , 70. 10.1186/s40360-020-00446-x

Rambaldi, Alessandro, Ribera, Josep-Maria, Kantarjian, Hagop M., Dombret, Hervé, Ottmann, Oliver G.

, Stein, Anthony S., Tuglus, Catherine A., Zhao, Xiaoyue, Kim, Christopher and Martinelli, Giovanni 2020. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Cancer 126 (2) , pp. 304-310. 10.1002/cncr.32558

Gidman, Wendy, Shah, Shweta, Zhang, Lirong, McKendrick, Jan, Cong, Ze, Cohan, David and Ottmann, Oliver

2019. Clinicians' perspectives on cure in adult patients with acute lymphoblastic leukemia with minimal residual disease: A Delphi Study. Advances in Therapy 36 (11) , pp. 3017-3029. 10.1007/s12325-019-01099-x

Mian, Afsar A., Baumann, Ines, Liebermann, Marcus, Grebien, Florian, Superti-Furga, Giulio, Ruthardt, Martin

, Ottmann, Oliver G.

and Hantschel, Oliver 2019. The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis. Leukemia 33 , pp. 2319-2323. 10.1038/s41375-019-0468-y

Pfeifer, H., Cazzaniga, G., van der Velden, V. H. J., Cayuela, J. M., Schäfer, B., Spinelli, O., Akiki, S., Avigad, S., Bendit, I., Borg, K., Cavé, H., Elia, L., Reshmi, S. C., Gerrard, G., Hayette, S., Hermanson, M., Juh, A., Jurcek, T., Chillón, M. C., Homburg, C., Martinelli, G., Kairisto, V., Lange, T., Lion, T., Mueller, M. C., Pane, F., Rai, L., Damm-Welk, C., Sacha, T., Schnittger, S., Touloumenidou, T., Valerhaugen, H., Vandenberghe, P., Zuna, J., Serve, H., Herrmann, E., Markovic, S., Dongen, J. J. M. van and Ottmann, O. G.

2019. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph?+?ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia 33 , pp. 1910-1922. 10.1038/s41375-019-0413-0

Döhner, Hartmut, Müller-Tidow, Carsten, Lübbert, Michael, Fiedler, Walter, Krämer, Alwin, Westermann, Jörg, Bug, Gesine, Schlenk, Richard F., Krug, Utz, Goeldner, Rainer-Georg, Hilbert, James, Taube, Tillmann and Ottmann, Oliver G.

2019. A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. British Journal of Haematology 185 (3) , pp. 583-587. 10.1111/bjh.15563

Ottmann, Oliver G.

, Müller-Tidow, Carsten, Krämer, Alwin, Schlenk, Richard F., Lübbert, Michael, Bug, Gesine, Krug, Utz, Bochtler, Tilmann, Voss, Florian, Taube, Tillmann, Liu, Dan, Garin-Chesa, Pilar and Döhner, Hartmut 2019. Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. British Journal of Haematology 184 (6) , pp. 1018-1021. 10.1111/bjh.15204

Cortes, Jorge E., Heidel, Florian H., Hellmann, Andrzej, Fiedler, Walter, Smith, B. Douglas, Robak, Tadeusz, Montesinos, Pau, Pollyea, Daniel A., DesJardins, Pierre, Ottmann, Oliver

, Ma, Weidong Wendy, Shaik, M. Naveed, Laird, A. Douglas, Zeremski, Mirjana, O'Connell, Ashleigh, Chan, Geoffrey and Heuser, Michael 2019. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33 , pp. 379-389. 10.1038/s41375-018-0312-9

Ottmann, Oliver

2018. Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balance. Lancet Haematology 5 (12) , e606-e607. 10.1016/S2352-3026(18)30181-9

Brown, Jennifer R., Hamadani, Mehdi, Hayslip, John, Janssens, Ann, Wagner-Johnston, Nina, Ottmann, Oliver

, Arnason, Jon, Tilly, Hervé, Millenson, Michael, Offner, Fritz, Gabrail, Nashat Y., Ganguly, Siddhartha, Ailawadh, Sikander, Kasar, Siddha, Kater, Arnon P., Doorduijn, Jeanette K., Gao, Lei, Lager, Joanne J., Wu, Bin, Egile, Coumaran and Kersten, Marie José 2018. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematology 5 (4) , e170-e180. 10.1016/S2352-3026(18)30030-9

Pfeifer, Heike, Raum, Katharina, Markovic, Sandra, Nowak, Verena, Fey, Stephanie, Obländer, Julia, Pressler, Jovita, Böhm, Verena, Brüggemann, Monika, Wunderle, Lydia, Hüttmann, Andreas, Wäsch, Ralph, Beck, Joachim, Stelljes, Matthias, Viardot, Andreas, Lang, Fabian, Hoelzer, Dieter, Hofmann, Wolf-Karsten, Serve, Hubert, Weiss, Christel, Goekbuget, Nicola, Ottmann, Oliver G.

and Nowak, Daniel 2018. Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood 131 (13) , pp. 1464-1475. 10.1182/blood-2017-07-796862

Legut, Mateusz, Dolton, Garry, Mian, Afsar, Ottmann, Oliver

and Sewell, Andrew

2018. CRISPR-mediated TCR replacement generates superior anticancer transgenic T-cells. Blood 131 (3) , pp. 311-322. 10.1182/blood-2017-05-787598

Schlenk, Richard, Krauter, Jürgen, Raffoux, Emmanuel, Kreuzer, Karl-Anton, Schaich, Markus, Noens, Lucien, Pabst, Thomas, Vusirikala, Madhuri, Bouscary, Didier, Spencer, Andrew, Candoni, Anna, Sierra Gil, Jorge, Berkowitz, Noah, Weber, Hans-Jochen and Ottmann, Oliver

2018. Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia, results from two clinical trials. Haematologica 103 , e25-e28. 10.3324/haematol.2017.172411

Ottmann, Oliver

, Saglio, Giuseppe, Apperley, Jane F., Arthur, Christopher, Bullorsky, Eduardo, Charbonnier, Aude, Dipersio, John F., Kantarjian, Hagop, Khoury, Hanna Jean, Kim, Dong-Wook, Healey, Diane, Strauss, Lewis and Cortes, Jorge E. 2018. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer Journal 8 (9) , 88. 10.1038/s41408-018-0122-3

Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M and Ottmann, Oliver

2017. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts. Leukemia 31 (12) , pp. 2799-2806. 10.1038/leu.2017.159

Nagel, Inga, Bartels, Marius, Duell, Johannes, Oberg, Hans-Heinrich, Ussat, Sandra, Bruckmueller, Henrike, Ottmann, Oliver

, Pfeifer, Heike, Trautmann, Heiko, Gökbuget, Nicola, Caliebe, Almuth, Kabelitz, Dieter, Kneba, Michael, Horst, Heinz-August, Hoelzer, Dieter, Topp, Max S., Cascorbi, Ingolf, Siebert, Reiner and Brüggemann, Monika 2017. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood 130 (18) , pp. 2027-2031. 10.1182/blood-2017-05-782888

Ottmann, Oliver

2017. Dasatinib and azacitidine followed by haploidentical stem cell transplant for chronic myeloid leukemia with evolving myelodysplasia: A case report and review of treatment options. American Journal of Case Reports 18 , pp. 1099-1109. 10.12659/AJCR.904956

Bug, G, Burchert, A, Wagner, E-M, Kröger, N, Berg, T, Güller, S, Metzelder, S K, Wolf, A, Hünecke, S, Bader, P, Schetelig, J, Serve, H and Ottmann, Oliver

2017. Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). Leukemia 31 (11) , pp. 2523-2525. 10.1038/leu.2017.242

Hantschel, Oliver and Ottmann, Oliver G.

2017. Allosterische Kinaseinhibitoren. Der Onkologe 23 (8) , pp. 626-631. 10.1007/s00761-017-0244-4

Both, Anna, Krauter, Jürgen, Damm, Frederik, Thol, Felicitas, Göhring, Gudrun, Heuser, Michael, Ottmann, Oliver

, Lübbert, Michael, Wattad, Mohammed, Kanz, Lothar, Schlimok, Günter, Raghavachar, Aruna, Fiedler, Walter, Kirchner, Hartmut, Brugger, Wolfram, Schlegelberger, Brigitte, Heil, Gerhard, Ganser, Arnold and Wagner, Katharina 2017. The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. Annals of Hematology 96 (6) , pp. 895-904. 10.1007/s00277-017-2967-0

Martinelli, Giovanni, Boissel, Nicolas, Chevallier, Patrice, Ottmann, Oliver

, Gökbuget, Nicola, Topp, Max S., Fielding, Adele K., Rambaldi, Alessandro, Ritchie, Ellen K., Papayannidis, Cristina, Sterling, Lulu Ren, Benjamin, Jonathan and Stein, Anthony 2017. Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. Journal of Clinical Oncology 35 (16) , pp. 1795-1802. 10.1200/JCO.2016.69.3531

Gökbuget, Nicola, Zugmaier, Gerhard, Klinger, Matthias, Kufer, Peter, Stelljes, Matthias, Viardot, Andreas, Horst, Heinz A., Neumann, Svenja, Brüggemann, Monika, Ottmann, Oliver

, Burmeister, Thomas, Wessiepe, Dorothea, Topp, Max S. and Bargou, Ralf 2017. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica 102 (4) , e132-e135. 10.3324/haematol.2016.153957

Lang, F, Wojcik, B, Bothur, S, Knecht, C, Falkenburg, J H F, Schroeder, T, Serve, H, Ottmann, Oliver

and Rieger, M A 2017. Plastic CD34 and CD38 expression in adult B-cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations. Leukemia 31 (3) , pp. 731-734. 10.1038/leu.2016.315

Oelsner, Sarah, Friede, Miriam E., Zhang, Congcong, Wagner, Juliane, Badura, Susanne, Bader, Peter, Ullrich, Evelyn, Ottmann, Oliver

, Klingemann, Hans, Tonn, Torsten and Wels, Winfried S. 2017. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy 19 (2) , pp. 235-249. 10.1016/j.jcyt.2016.10.009

Oelsner, Sarah, Wagner, Juliane, Friede, Miriam E., Pfirrmann, Verena, Genssler, Sabrina, Rettinger, Eva, Buchholz, Christian J., Pfeifer, Heike, Schubert, Ralf, Ottmann, Oliver

, Ullrich, Evelyn, Bader, Peter and Wels, Winfried S. 2016. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival. International Journal of Cancer 139 (8) , pp. 1799-1809. 10.1002/ijc.30217

Giebel, Sebastian, Czyz, Anna, Ottmann, Oliver

, Baron, Frederic, Brissot, Eolia, Ciceri, Fabio, Cornelissen, Jan J., Esteve, Jordi, Gorin, Norbert-Claude, Savani, Bipin, Schmid, Christoph, Mohty, Mohamad and Nagler, Arnon 2016. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for blood and marrow transplantation. Cancer 122 (19) , pp. 2941-2951. 10.1002/cncr.30130

Wojcik, Bartosch, Lang, Fabian, Oellerich, Thomas, Falkenburg, J. H., Brueggemann, Monika, Schroeder, Timm, Serve, Hubert, Ottmann, Oliver

and Rieger, Michael 2016. Plastic surface marker expression in adult acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations. Experimental Hematology 44 (9) , S108. 10.1016/j.exphem.2016.06.240

Rousselot, Philippe, Coude, Marie Magdelaine, Gokbuget, Nicola, Passerini, Carlo Gambacorti, Hayette, Sandrine, Cayuela, Jean-Michel, Huguet, Francoise, Leguay, Thibaut, Chevallier, Patrice, Salanoubat, Celia, Bonmati, Caroline, Alexis, Magda, Hunault, Mathilde, Glaisner, Sylvie, Agape, Philippe, Berthou, Christian, Jourdan, Eric, Fernandes, Jose, Sutton, Laurent, Banos, Anne, Reman, Oumedaly, Lioure, Bruno, Thomas, Xavier, Ifrah, Norbert, Lafage-Pochitaloff, Marina, Bornand, Anne, Morisset, Laure, Robin, Valerie, Pfeifer, Heike, Delannoy, Andre, Ribera, Josep, Bassan, Renato, Delord, Marc, Hoelzer, Dieter, Dombret, Herve and Ottmann, Oliver

2016. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood 128 (6) , pp. 774-782. 10.1182/blood-2016-02-700153

Haense, N., Atmaca, A., Pauligk, C., Steinmetz, K., Marmé, F., Haag, G. M., Rieger, M., Ottmann, Oliver

, Ruf, P., Lindhofer, H. and Al-Batran, S.-E. 2016. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer 16 (1) , p. 420. 10.1186/s12885-016-2449-0

Romanski, Annette, Uherek, Christoph, Bug, Gesine, Seifried, Erhard, Klingemann, Hans, Wels, Winfried S., Ottmann, Oliver

and Tonn, Torsten 2016. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. Journal of Cellular and Molecular Medicine 20 (7) , pp. 1287-1294. 10.1111/jcmm.12810

Haberbosch, Isabella, Rafiei, Anahita, Oancea, Claudia

, Ottmann, Oliver

, Ruthardt, Martin

and Mian, Afsar 2016. BCR: a new target in resistance mediated by BCR/ABL-315I? Genes & Cancer 7 (1-2) , pp. 36-46.

Vetter, Tina, Borowski, Andreas, Wohlmann, Andreas, Ranjan, Nilabh, Kuepper, Michael, Badura, Susanne, Ottmann, Oliver

and Friedrich, Karlheinz 2016. Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients. Leukemia Research 40 , pp. 38-43. 10.1016/j.leukres.2015.10.003

Leibundgut, Elisabeth Oppliger, Haubitz, Monika, Burington, Bart, Ottmann, Oliver

, Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A., Roeth, Alexander, Snyder, David S. and Baerlocher, Gabriela M. 2015. Dynamics of mutations in patients with ET treated with Imetelstat. Blood 126 (23) , 57.

Bug, Gesine, Burchert, Andreas, Wagner, Eva-Maria, Kroeger, Nicolaus, Jedlickova, Zuzana, Gueller, Saskia, Metzelder, Stephan, Wolf, Andrea, Bader, Peter, Huenecke, Sabine, Serve, Hubert and Ottmann, Oliver

2015. Phase I/II Study of the Deacetylase Inhibitor Panobinostat As maintenance therapy after an allogeneic stem cell transplantation in patients with high-risk MDS or AML: The Panobest-Trial. Blood 126 (23) , 4344.

Giagounidis, Aristoteles, Platzbecker, Uwe, Germing, Ulrich, Goetze, Katharina, Kiewe, Philipp, Mayer, Karin Tina, Ottmann, Oliver

, Radsak, Markus, Wolff, Thomas, Haase, Detlef, Hankin, Monty, Wilson, Dawn, Zhang, Xiaosha, Laadem, Adberrahmane, Sherman, Matthew L. and Attie, Kenneth M. 2015. Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. Blood 126 (23) , 92.

Platzbecker, Uwe, Germing, Ulrich, Giagounidis, Aristoteles, Goetze, Katharina, Kiewe, Philipp, Mayer, Karin Tina, Ottmann, Oliver

, Radsak, Markus, Wolff, Thomas, Haase, Detlef, Hankin, Monty, Wilson, Dawn, Zhang, Xiaosha, Laadem, Abderrahmane, Sherman, Matthew L. and Attie, Kenneth M. 2015. Biomarkers of ineffective erythropoiesis predict response to Luspatercept in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): final results from the phase 2 PACE-MDS study. Blood 126 (23) , 2862.

Martinelli, Giovanni, Dombret, Herve, Chevallier, Patrice, Ottmann, Oliver

, Goekbuget, Nicola, Topp, Max S., Fielding, Adele K., Sterling, Lulu Ren, Benjamin, Jonathan and Stein, Anthony Selwyn 2015. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) following treatment with blinatumomab: results from a Phase 2 single-arm, multicenter study (ALCANTARA). Blood 126 (23) , 679.

Garcia-Manero, Guillermo, Sekeres, Mikkael A., Egyed, Miklos, Alimena, Giuliana, Graux, Carlos, Cavenagh, Jamie D., Salman, Huda, Illes, Arpad, Fenaux, Pierre, DeAngelo, Daniel J., Stauder, Reinhard, Yee, Karen, Zhu, Nancy Y., Lee, Je-Hwan, Valcarcel, David, MacWhannell, Alan, Borbenyi, Zita, Wegener, Antje, Gazi, Lucien, Acharyya, Suddhasatta, Binlich, Florence and Ottmann, Oliver

2015. Panobinostat plus azacitidine in adult patients with MDS, CMML, or AML: results of a Phase 2b study. Blood 126 (23) , 2861.

Ottmann, Oliver

, Alimena, Giuliana, DeAngelo, Daniel J., Goh, Yeow-Tee, Heinrich, Michael C., Hochhaus, Andreas, Hughes, Timothy P., Mahon, Francois-Xavier, Mauro, Michael J., Minami, Hironobu, Nguyen, Marie Huong, Rea, Delphine, Steegmann, Juan Luis, Chatterjee, Arkendu, Iyer, Varsha, Martinez, Noelia, Vanasse, Gary J. and Dong-Wook, Kim 2015. ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single - agent activity in a Phase I study of patients with CML with failure of prior TKI therapy. Blood 126 (23) , 138.

Bartels, M., Nagel, I., Ussat, S., Ottmann, Oliver

, Pfeifer, H., Trautmann, H., Boettcher, S., Goekbuget, N., Kneba, M., Oberg, H. -H., Siebert, R. and Brueggemann, M. 2015. Deletions of CDKN2A/B and PAX5 are frequently restricted to the CD19+compartment and associated with concurrent deletions of ABL in adult BCR-ABL plus BCP-ALL. Oncology Research and Treatment 38 (S5) , pp. 90-91. 10.1159/000439070

Dengler, J., Le Coutre, P., Mueller, M. C., Stegelmann, F., Ulshoeer, T., Sauer, A., Reichert, D., Schwinger, U., Waller, C. F., Schardt, C., Losem, C., Schneider-Kappus, W., Stern, S., Vehling-Kaiser, U., Meincke, M., Frank, O. and Ottmann, Oliver

2015. Efficacy and safety of nilotinib in routine healthcare: Treatment of CML patients (pts) failing prior therapy - Results of the non-interventional TARGET study. Oncology Research and Treatment 38 (S5) , pp. 132-133. 10.1159/000439070

Pfeifer, H., Cayuela, J. -M., Spiekermann, K., Beck, J., Jung, W., Viardot, A., Schaefer-Eckhart, K., Reichle, A., Maury, S., Schmitz, N., Heidenreich, D., Panse, J., Junghanss, C., Raffoux, E., Suarez, F., Guillerm, G., Alexis, M., Lissandre, S., Huguet, F., Isnard, F., Lepetre, S., Escofffre-Barbe, M., Ribera, J. -M., Goekbuget, N., Dombret, H., Hoelzer, D., Rousselot, P. and Ottmann, Oliver

2015. European working group for adult ALL phase II trial of nilotinib in combination with chemotherapy for first-line treatment in elderly patients with de novo Philadelphiachromosome positive acute lymphoblastic leukemia (EWALL-PH-02). Oncology Research and Treatment 38 (S5) , p. 88. 10.1159/000439070

Baerlocher, Gabriela M., Oppliger Leibundgut, Elisabeth, Ottmann, Oliver G.

, Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A., Röth, Alexander, Daskalakis, Michael, Burington, Bart, Stuart, Monic and Snyder, David S. 2015. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. New England Journal of Medicine 373 , pp. 920-928. 10.1056/NEJMoa1503479

Seggewiss-Bernhardt, Ruth, Bargou, Ralf C., Goh, Yeow Tee, Stewart, A. Keith, Spencer, Andrew, Alegre, Adrian, Blade, Joan, Ottmann, Oliver

, Fernandez-Ibarra, Cristina, Lu, Hong, Pain, Scott, Akimov, Mikhail and Iyer, Swaminathan Padmanabhan 2015. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer 121 (13) , pp. 2185-2192. 10.1002/cncr.29339

Fiedler, W., Heuser, M., Ottmann, Oliver

, Kebenko, M., Thol, F., Trummer, A., Brandts, C., Bokemeyer, C., Theile, S. and Kranich, A. 2015. Preliminary phase II results of Ara-C and idarubicin in combination with selective inhibitor of nuclear export (SINE) compound selinexor (KPT-330) in patients with relapsed or refractory AML. Haematologica 100 , p. 221.

Bartels, M., Nagel, I., Ussat, S., Ottmann, Oliver

, Pfeifer, H., Trautmann, H., Boettcher, S., Goekbuget, N., Kneba, M., Oberg, H. H., Siebert, R. and Brueggemann, M. 2015. Clonal Architectures Of Bcr-Abl Plus Bcp-All: Implications For Anti B-Cell Directed Therapy. Haematologica 100 (S1) , p. 27.

Pfeifer, H., Rousselot, P., Cayuela, J. M., Karsten, S., Beck, J., Jung, W. E., Viardot, A., Schaefer-Eckart, K., Reichle, A., Maury, S., Schmitz, N., Heidenreich, D., Panse, J., Junghanss, C., Raffoux, E., Suarez, F., Guillerm, G., Alexis, M., Lissandre, S., Huguet, F., Isnard, F., Lepretre, S., Escoffre-Barbe, M., Ribera, J. M., Goekbuget, N., Hoelzer, D., Dombret, H. and Ottmann, Oliver

2015. Nilotinib In Combination With Chemotherapy For First-Line Treatment In Elderly Patients With Philadelphia-Positive All: Results Of The European Working Group For Adult All(Ewall-Ph-02). Haematologica 100 (S1) , pp. 6-7.

Ottmann, Oliver

, Charbonnier, A., Stegelmann, F., Breccia, M., Steegmann, J. L., Olavarria, E., Jevtic, S., Cota, M., Scheuer, N. and Lipton, J. H. 2015. Smoothened (Smo) Inhibitor Lde225 Combined With Nilotinib In Patients With Chronic Myeloid Leukemia (Cml) Resistant/Intolerant (R/I) To At Least 1 Prior Tyrosine Kinase Inhibitor: A Phase 1B Study. Haematologica 100 (S1) , pp. 62-63.

DeAngelo, Daniel J., Sekeres, Mikkael A., Ottmann, Oliver

, Sanz, Miguel A., Naoe, Tomoki, Taube, Tillmann, Belsack, Valerie, Ge, Miaomiao and Doehner, Hartmut 2015. Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy. Clinical Lymphoma, Myeloma and Leukemia 15 , S194-S194. 10.1016/j.clml.2015.04.046

Mian, A. A., Rafiei, A., Haberbosch, I., Zeifman, A., Titov, I., Stroylov, V., Metodieva, A., Stroganov, O., Novikov, F., Brill, B., Chilov, G., Hoelzer, D., Ottmann, O. G.

and Ruthardt, M.

2015. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia 29 (5) , pp. 1104-1114. 10.1038/leu.2014.326

Rafiei, Anahita, Mian, Afsar Ali, Doering, Claudia, Metodieva, Anna, Oancea, Claudia

, Thalheimer, Frederic B., Hansmann, Martin Leo, Ottmann, Oliver

and Ruthardt, Martin

2015. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive Acute Lymphatic Leukemia. PLOS Genetics 11 (4) , e1005144. 10.1371/journal.pgen.1005144

Platzbecker, U., Germing, U., Giagounidis, A., Goetze, K., Kiewe, P., Mayer, K., Ottmann, Oliver

, Radsak, M., Wolff, T., Haase, D., Hankin, M., Wilson, D., Zhang, X., Laadem, A., Sherman, M. and Attie, K. 2015. Luspatercept increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): preliminary results from a phase 2 study. Leukemia Research 39 (S1) , S25. 10.1016/S0145-2126(15)30054-0

Thol, Felicitas, Scherr, Michaela, Kirchner, Aylin, Shahswar, Rabia, Battmer, Karin, Kade, Sofia, Chaturvedi, Anuhar, Koenecke, Christian, Stadler, Michael, Platzbecker, Uwe, Thiede, Christian, Schroeder, Thomas, Kobbe, Guido, Bug, Gesine, Ottmann, Oliver

, Hofmann, Wolf-Karsten, Kroeger, Nicolaus, Fiedler, Walter, Schlenk, Richard, Doehner, Konstanze, Doehner, Hartmut, Krauter, Juergen, Eder, Matthias, Ganser, Arnold and Heuser, Michael 2015. Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. Haematologica 100 (4) , E122-E124. 10.3324/haematol.2014.120345

Bug, G., Burchert, A., Wagner, E. M., Kroeger, N., Jedlickova, Z., Gueller, S., Wolf, A., Huenecke, S., Bader, P., Serve, H. and Ottmann, Oliver

2015. Panobinostat as maintenance therapy after allogeneic stem cell transplantation in patients with high-risk MDS or AML: Results from the dose-escalation part of the PANOBEST trial. Bone Marrow Transplantation 50 , S59-S59. 10.1038/bmt.2015.27

Brissot, Eolia, Labopin, Myriam, Beckers, Marielle M., Socie, Gerard, Rambaldi, Alessandro, Volin, Liisa, Finke, Juergen, Lenhoff, Stig, Kroeger, Nicolaus, Ossenkoppele, Gert J., Craddock, Charles F., Yakoub-Agha, Ibrahim, Gurman, Gunhan, Russell, Nigel H., Aljurf, Mahmoud, Potter, Michael N., Nagler, Armon, Ottmann, Oliver

, Cornelissen, Jan J., Esteve, Jordi and Mohty, Mohamad 2015. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica 100 (3) , pp. 392-399. 10.3324/haematol.2014.116954

Mian, Afsar A., Haberboseh, Isabella, Kidan, Noa, Khamaisic, Hazem, Regev, Ofer, Nickola, Meshel, Gal, Maayan, Bloch, Etai, Ratiei, Anahita, Silani, Daryuseh, Ottmann, Oliver

, Biondi, Ricardo, Ruthardt, Martin

and Mahaina, Jamal 2015. Potential use of allosteric inhibitors as strategy to overcome drug resistance in Ph-positive leukemia. International Journal of Molecular Medicine 36 , S26-S26.

Mian, Afsar, Rafiei, Anahita, Oancea, Claudia

, Ottmann, Oliver

and Ruthardt, Martin

2014. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome positive Acute Lymphatic Leukemia. Blood 124 (21) , 2402.

Tesanovic, Tamara, Badura, Susanne, Oellerich, Thomas, Doering, Claudia, Ruthardt, Martin and Ottmann, Oliver

2014. Mechanisms of antileukemic activity of the multikinase inhibitors Dasatinib and Ponatinib in Acute Lymphoblastic Leukemia (ALL) harboring the E2A-PBX1 fusion gene. Blood 124 (21) , 3595.

Baerlocher, Gabriela M., Haubitz, Monika, Ottmann, Oliver

, Odenike, Olatoyosi, Roeth, Alexander, McDevitt, Michael A., Shih, Ted, Burington, Bart, Morfeld, Dianne, Batra, Neeru, Snyder, David and Leibundgut, Elisabeth Oppliger 2014. Monitoring of Calr Allele burden in patients with Essential Thrombocythemia treated with Imetelstat, a telomerase inhibitor, reveals rapid and substantial molecular responses. Blood 124 (21) , 408.

Zweidler-McKay, Patrick A., DeAngelo, Daniel J., Douer, Dan, Dombret, Herve, Ottmann, Oliver

, Vey, Norbert, Thomas, Deborah A., Zhu, Lili, Huang, Fei, Bajaj, Gaurav and Fischer, Bruce S. 2014. The safety and activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with anti-notch activity, in patients with relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): initial results of a phase 1 trial. Blood 124 (21) , 968.

Wojcik, Bartosch, Lang, Fabian, Badura, Susanne, Vogel, Anja, Tesanovic, Tamara, Oellerich, Thomas, Schroeder, Timm, Falkenburg, J. H. Frederik, Brueggemann, Monika, Ottmann, Oliver

and Rieger, Michael A. 2014. Functional analysis of the subclonal architecture of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) at a single cell level. Blood 124 (21) , 3778.

Mian, Afsar, Haberbosch, Isabella, Ottmann, Oliver

and Ruthardt, Martin 2014. Transphosphorylation of endogenous BCR mediates the effect of T315I on the transformation potential of BCR/ABL. Blood 124 (21) , 4523.

Platzbecker, U., Germing, U., Giagounidis, A., Goetze, K., Kiewe, P., Mayer, K., Ottmann, Oliver

, Radsak, M. P., Wolff, T., Haase, D., Hankin, M., Wilson, D. M., Laadem, A., Sherman, M. L. and Attie, K. M. 2014. ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): preliminary results from a phase 2 study. Blood 124 (21) , 411.

Oancea, Claudia

, Heinssmann, Maria, Guillen, Nathalie, Ottmann, Oliver

and Ruthardt, Martin 2014. The GSK3 beta-phosphorylation sites in the dek-portion are indispensable for the leukemogenic potential of the dek/can fusion protein in t(6;9)-positive acute myeloid leukemia [Abstract]. Blood 124 (21)

Platzbecker, U., Al-Ali, H. K., Gattermann, N., Haase, D., Janzen, V., Krauter, J., Goetze, K., Schlenk, R., Nolte, F., Letsch, A., Ottmann, Oliver

, Kuendgen, A., Luebbert, M., Germing, U., Wermke, M., Reinhard, H., Weiss, C., Lieder, K., Ehninger, G., Leismann, O. and Giagounidis, A. 2014. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients [Letter]. Leukemia 28 (3) , pp. 696-698. 10.1038/leu.2013.325

Scherr, M., Elder, A., Battmer, K., Barzan, D., Bomken, S., Ricke-Hoch, M., Schroeder, A., Venturini, L., Blair, H. J., Vormoor, J., Ottmann, Oliver

, Ganser, A., Pich, A., Hilfiker-Kleiner, D., Heidenreich, O. and Eder, M. 2014. Differential expression of miR-17 similar to 92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia 28 (3) , pp. 554-565. 10.1038/leu.2013.361

Bug, Gesine, Koschmieder, Steffen, Krauter, Juergen, Heuser, Michael, Thol, Felicitas, Wiebe, Stefanie, Hofmann, Wolf-Karsten, Klein, Stefan A., Wegener, Gerd, Goehring, Gudrun, Heit, Wolfgang, Hoelzer, Dieter, Ganser, Arnold and Ottmann, Oliver

2014. Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. Annals of Hematology 93 (2) , pp. 193-202. 10.1007/s00277-013-1873-3

Stegelmann, F., Dengler, J., Le Coutre, P., Mueller, M. C., Sauer, A., Schwinger, U., Losem, C., Schneider-Kappus, W., Stern, S., Vehling-Kaiser, U., Meincke, M., Frank, O. and Ottmann, Oliver

2014. Follow-up of the non-interventional TARGET study – efficacy and safety of nilotinib in routine clinical management of CML patients (pts) failing prior therapy. Oncology Research and Treatment 37 (Supp 1) , p. 84.

Jabbour, Elias, Ottmann, Oliver

, Deininger, Michael and Hochhaus, Andreas 2014. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica 99 (1) , pp. 7-18. 10.3324/haematol.2013.087171

Ottmann, Oliver

, Pfeifer, Heike, Cayuela, Jean-Michel, Spiekermann, Karsten, Beck, Joachim, Jung, Wolfram E., Viardot, Andreas, Kerstin, Schaefer-Eckart, Reichle, Albrecht, Maury, Sebastien, Schmitz, Norbert, Heidenreich, Daniela, Panse, Jens, Junghanss, Christian, Raffoux, Emmanuel, Suarez, Felipe, Guillerm, Gaeelle, Alexis, Magda, Lissandre, Severine, Huguet, Francoise, Isnard, Francoise, Lepretre, Stephane, Escoffre-Barbe, Martine, Ribera, Josep-Maria, Goekbuget, Nicola, Dombret, Herve, Hoelzer, Dieter and Rousselot, Philippe 2014. Nilotinib (Tasigna®) and chemotherapy for first-line treatment in elderly patients with De Novo Philadelphia chromosome/BCR-ABL1 positive acute Lymphoblastic Leukemia (ALL): A trial of the European Working Group for Adult ALL (EWALL-PH-02). Blood 124 (21) , p. 798.

Doehner, Hartmut, Luebbert, Michael, Fiedler, Walter, Fouillard, Loic, Haaland, Alf, Brandwein, Joseph M., Lepretre, Stephane, Reman, Oumedaly, Turlure, Pascal, Ottmann, Oliver

, Mueller-Tidow, Carsten, Kraemer, Alwin, Raffoux, Emmanuel, Doehner, Konstanze, Schlenk, Richard F., Voss, Florian, Taube, Tillmann, Fritsch, Holger and Maertens, Johan 2014. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood 124 (9) , pp. 1426-1433. 10.1182/blood-2014-03-560557

Badura, Susanne, Tesanovic, Tamara, Pfeifer, Heike, Wystub, Sylvia, Nijmeijer, Bart A., Liebermann, Marcus, Falkenburg, J. H. Frederik, Ruthardt, Martin

and Ottmann, Oliver G.

2013. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. PLOS ONE 8 (11) , e80070. 10.1371/journal.pone.0080070

Mian, Afsar Ali, Metodieva, Anna, Badura, Susanne, Khateb, Mamduh, Ruimi, Nili, Najajreh, Yousef, Ottmann, Oliver Gerhard

, Mahajna, Jamal and Ruthardt, Martin

2012. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer 12 (411) 10.1186/1471-2407-12-411

Mian, Afsar A., Metodieva, Anna, Najajreh, Yousef, Ottmann, Oliver G.

, Mahajna, Jamal and Ruthardt, Martin

2012. p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica 97 (2) 10.3324/haematol.2011.047191

Mian, A A, Oancea, C, Zhao, Z, Ottmann, O G

and Ruthardt, M

2009. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia 23 , 2242–2247. 10.1038/leu.2009.194

Mian, A A, Schüll, M, Zhao, Z, Oancea, C, Hundertmark, A, Beissert, T, Ottmann, O G

and Ruthardt, M

2009. The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia 23 , 1614–1621. 10.1038/leu.2009.69

Gwanmesia, Patricia Mambou, Romanski, Annette, Schwarz, Kerstin, Bacic, Biserka, Ruthardt, Martin

and Ottmann, Oliver G

2009. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines. BMC Cancer 9 , 53. 10.1186/1471-2407-9-53

Bug, Gesine, Schwarz, Kerstin, Schoch, Claudia, Kampfmann, Manuela, Henschler, Reinhard, Hoelzer, Dieter, Ottmann, Oliver G.

and Ruthardt, Martin

2007. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 92 (4) 10.3324/haematol.10758

Bug, Gesine, Ritter, Markus, Wassmann, Barbara, Schoch, Claudia, Heinzel, Thorsten, Schwarz, Kerstin, Romanski, Annette, Kramer, Oliver H., Kampfmann, Manuela, Hoelzer, Dieter, Neubauer, Andreas, Ruthardt, Martin

and Ottmann, Oliver G.

2005. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104 (12) , pp. 2717-2725. 10.1002/cncr.21589

Puccetti, Elena, Zheng, Xiaomin, Brambilla, Daria, Seshire, Anita, Beissert, Tim, Boehrer, Simone, Nürnberger, Heike, Hoelzer, Dieter, Ottmann, Oliver Gerhard

, Nervi, Clara and Ruthardt, Martin

2005. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha. Cancer Research 65 (14) , 6080–6088. 10.1158/0008-5472.CAN-04-3631

Bug, Gesine, Gül, Hilal, Schwarz, Kerstin, Pfeifer, Heike, Kampfmann, Manuela, Zheng, Xiaomin, Beissert, Tim, Boehrer, Simone, Hoelzer, Dieter, Ottmann, Oliver Gerhard

and Ruthardt, Martin

2005. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Research 65 (7) , 2537–2541. 10.1158/0008-5472.CAN-04-3011

Zheng, Xiaomin, Beissert, Tim, Kukoc-Zivojnov, Natasa, Puccetti, Elena, Altschmied, Joachim, Strolz, Corinna, Boehrer, Simone, Gul, Hilal, Schneider, Orinta, Ottmann, Oliver Gerhard

, Hoelzer, Dieter, Henschler, Reinhard and Ruthardt, Martin

2004. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 103 (9) , 3535–3543. 10.1182/blood-2003-09-3335

Romanski, Annette, Bacic, Biserka, Bug, Gesine, Pfeifer, Heike, Gul, Hilal, Remiszewski, Stacy, Hoelzer, Dieter, Atadja, Peter, Ruthardt, Martin

and Ottmann, Oliver G

2004. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 89 (4) , pp. 419-426.

Beissert, Tim, Puccetti, Elena, Bianchini, Andrea, Güller, Saskia, Boehrer, Simone, Hoelzer, Dieter, Ottmann, Oliver Gerhard

, Nervi, Clara and Ruthardt, Martin

2003. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. Blood 102 (8) , 2985–2993. 10.1182/blood-2003-03-0811

Puccetti, Elena, Beissert, Tim, Güller, Saskia, Li, Jun E, Hoelzer, Dieter, Ottmann, Oliver G

and Ruthardt, Martin

2003. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. Oncogene 22 , 6900–6908. 10.1038/sj.onc.1206747

Puccetti, Elena, Obradovic, Darja, Beissert, Tim, Bianchini, Andrea, Washburn, Birgit, Chiaradonna, Ferdinando, Boehrer, Simone, Hoelzer, Dieter, Ottmann, Oliver Gerhard

, Pelicci, Pier Giuseppe, Nervi, Clara and Ruthardt, Martin

2002. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Research 62 (23) , 7050–7058.

Möller, Burkhard, Kukoc-Zivojnov, Natasa, Okamgba, Stella, Kessler, Uta, Puccetti, Elena, Ottmann, Oliver G.

, Kaltwasser, Joachim P., Hoelzer, Dieter and Ruthardt, Martin

2002. Folinic acid antagonizes methotrexate-induced differentiation of monocyte progenitors. Rheumatology International 22 , 60–67. 10.1007/s00296-002-0188-9

Puccetti, Elena, Güller, Saskia, Orleth, Anette, Brüggenolte, Nicole, Hoelzer, Dieter, Ottmann, Oliver Gerhard

and Ruthardt, Martin

2000. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Research 60 (13) , 3409–3413.

This list was generated on Thu Nov 21 08:26:13 2024 GMT.